Royalty Pharma plc Net Income
Royalty Pharma plc (RPRX) reported Net Income of $17.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- Royalty Pharma plc net income (loss) attributable to parent for the quarter ending 2026-06-30 was $17.88M, a 44.42% decline year-over-year.
- Royalty Pharma plc net income (loss) attributable to parent for the quarter ending 2026-03-31 was $294.69M, a 23.12% increase year-over-year.
- Royalty Pharma plc net income (loss) attributable to parent for the quarter ending 2025-12-31 was $214.21M, a 2.88% increase year-over-year.
- Royalty Pharma plc net income (loss) attributable to parent for the quarter ending 2025-09-30 was $288.22M, a 47.02% decline year-over-year.
- Royalty Pharma plc net income (loss) attributable to parent for fiscal 2025 was $770.95M, a 10.25% decline from fiscal 2024.
- Royalty Pharma plc net income (loss) attributable to parent for fiscal 2024 was $858.98M, a 24.31% decline from fiscal 2023.
- Royalty Pharma plc net income (loss) attributable to parent for fiscal 2023 was $1.13B, a 2549.50% increase from fiscal 2022.
- Royalty Pharma plc net income (loss) attributable to parent for fiscal 2022 was $42.83M, a 93.09% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $17.88M 10-Q · filed 2026-08-05 | $312.57M 10-Q · filed 2026-08-05 | $526.78M derived: sum of 3 quarters · filed 2026-08-05 | $815.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $294.69M 10-Q · filed 2026-05-06 | $508.89M derived: sum of 2 quarters · filed 2026-05-06 | $797.11M derived: sum of 3 quarters · filed 2026-05-06 | $829.29M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $214.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $502.42M derived: sum of 2 quarters · filed 2026-02-11 | $534.60M derived: sum of 3 quarters · filed 2026-08-05 | $770.95M 10-K · filed 2026-02-11 | ||
| 2025-09-30 | $288.22M 10-Q · filed 2025-11-05 | $320.39M derived: sum of 2 quarters · filed 2026-08-05 | $556.74M 10-Q · filed 2025-11-05 | $767.96M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | $32.18M 10-Q · filed 2026-08-05 | $30.18M 10-Q · filed 2025-08-06 | $271.52M 10-Q · filed 2026-08-05 | $268.52M 10-Q · filed 2025-08-06 | $479.74M derived: sum of 3 quarters · filed 2026-08-05 | $1.02B derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $239.35M 10-Q · filed 2026-05-06 | $238.35M 10-Q · filed 2025-05-08 | $447.56M derived: sum of 2 quarters · filed 2026-05-06 | $991.55M derived: sum of 3 quarters · filed 2026-05-06 | $1.09B derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $208.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $752.20M derived: sum of 2 quarters · filed 2026-02-11 | $854.21M derived: sum of 3 quarters · filed 2026-02-11 | $858.98M 10-K · filed 2026-02-11 | ||
| 2024-09-30 | $543.99M 10-Q · filed 2025-11-05 | $645.99M derived: sum of 2 quarters · filed 2025-11-05 | $650.77M 10-Q · filed 2025-11-05 | $1.15B derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-06-30 | $102.00M 10-Q · filed 2025-08-06 | $106.78M 10-Q · filed 2025-08-06 | $601.12M derived: sum of 3 quarters · filed 2026-02-11 | $673.24M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2024-03-31 | $4.78M 10-Q · filed 2025-05-08 | $499.12M derived: sum of 2 quarters · filed 2026-02-11 | $571.23M derived: sum of 3 quarters · filed 2026-02-11 | $798.86M derived: sum of 4 quarters · filed 2026-02-11 | ||
| 2023-12-31 | $494.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $566.45M derived: sum of 2 quarters · filed 2026-02-11 | $794.08M derived: sum of 3 quarters · filed 2026-02-11 | $1.13B 10-K · filed 2026-02-11 | ||
| 2023-09-30 | $72.11M 10-Q · filed 2024-11-06 | $299.74M derived: sum of 2 quarters · filed 2024-11-06 | $640.49M 10-Q · filed 2024-11-06 | $184.41M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-06-30 | $227.63M 10-Q · filed 2024-08-08 | $568.38M 10-Q · filed 2024-08-08 | $112.30M derived: sum of 3 quarters · filed 2025-02-12 | $254.95M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2023-03-31 | $340.75M 10-Q · filed 2024-05-09 | -$115.33M derived: sum of 2 quarters · filed 2025-02-12 | $27.32M derived: sum of 3 quarters · filed 2025-02-12 | $331.83M derived: sum of 4 quarters · filed 2025-02-12 | ||
| 2022-12-31 | -$456.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$313.43M derived: sum of 2 quarters · filed 2025-02-12 | -$8.93M derived: sum of 3 quarters · filed 2025-02-12 | $42.83M 10-K · filed 2025-02-12 | ||
| 2022-09-30 | $142.65M 10-Q · filed 2023-11-08 | $447.15M derived: sum of 2 quarters · filed 2023-11-08 | $498.92M 10-Q · filed 2023-11-08 | $506.82M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-06-30 | $304.50M 10-Q · filed 2023-08-08 | $356.26M 10-Q · filed 2023-08-08 | $364.17M derived: sum of 3 quarters · filed 2024-02-15 | $466.10M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2022-03-31 | $51.76M 10-Q · filed 2023-05-09 | $59.66M derived: sum of 2 quarters · filed 2024-02-15 | $161.59M derived: sum of 3 quarters · filed 2024-02-15 | $602.37M derived: sum of 4 quarters · filed 2024-02-15 | ||
| 2021-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $109.83M derived: sum of 2 quarters · filed 2024-02-15 | $550.61M derived: sum of 3 quarters · filed 2024-02-15 | $619.73M 10-K · filed 2024-02-15 | ||
| 2021-09-30 | $101.93M 10-Q · filed 2022-11-08 | $542.71M derived: sum of 2 quarters · filed 2022-11-08 | $611.82M 10-Q · filed 2022-11-08 | $782.92M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-06-30 | $440.78M 10-Q · filed 2022-08-04 | $509.89M 10-Q · filed 2022-08-04 | $680.99M derived: sum of 3 quarters · filed 2023-02-15 | $971.62M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2021-03-31 | $69.12M 10-Q · filed 2022-05-05 | $240.21M derived: sum of 2 quarters · filed 2023-02-15 | $530.85M derived: sum of 3 quarters · filed 2023-02-15 | $972.92M derived: sum of 4 quarters · filed 2023-02-15 | ||
| 2020-12-31 | $171.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $461.73M derived: sum of 2 quarters · filed 2023-02-15 | $903.80M derived: sum of 3 quarters · filed 2023-02-15 | $975.04M 10-K · filed 2023-02-15 | ||
| 2020-09-30 | $290.63M 10-Q · filed 2021-11-10 | $732.71M derived: sum of 2 quarters · filed 2021-11-10 | $803.95M 10-Q · filed 2021-11-10 | $2.22B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-06-30 | $442.07M 10-Q · filed 2021-08-11 | $513.31M 10-Q · filed 2021-08-11 | $1.93B derived: sum of 3 quarters · filed 2022-02-15 | $2.34B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2020-03-31 | $71.24M 10-Q · filed 2021-05-11 | $1.49B derived: sum of 2 quarters · filed 2022-02-15 | $1.90B derived: sum of 3 quarters · filed 2022-02-15 | $2.05B derived: sum of 4 quarters · filed 2022-02-15 | ||
| 2019-12-31 | $1.42B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $1.83B derived: sum of 2 quarters · filed 2022-02-15 | $1.98B derived: sum of 3 quarters · filed 2022-02-15 | $2.35B 10-K · filed 2022-02-15 | ||
| 2019-09-30 | $408.98M 10-Q · filed 2020-11-12 | $560.70M derived: sum of 2 quarters · filed 2020-11-12 | $928.14M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | $151.71M 10-Q · filed 2020-08-12 | $519.16M 10-Q · filed 2020-08-12 | ||||
| 2018-12-31 | $1.38B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |